Guardant Health and Merck sign global deal to co-develop cancer companion diagnostics
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
XenoTherapeutics’ takeover of Repare wins near-unanimous vote: What’s at stake for the pipeline
Repare shareholders approve XenoTherapeutics deal. Find out how this nonprofit acquisition could reshape oncology pipeline models.
Pierre Fabre and Iktos partner on AI-designed small-molecule cancer therapies
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Why Naveris’s NavDx performance outcomes could alter HPV cancer follow‑up standards
See how Naveris’s NavDx ctHPV DNA results are reshaping HPV cancer surveillance and what this means for clinicians, payers, and precision oncology adoption.
HUTCHMED’s fanregratinib wins priority review in China for intrahepatic cholangiocarcinoma
HUTCHMED (China) Limited announced on December 29, 2025, that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for fanregratinib (HMPL-453) with priority review for second-line treatment of adult patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement. The NDA submission is based on a Phase II registration study in China […]
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in […]
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
Rubraca’s FDA approval before chemo in BRCA-mutated prostate cancer could reshape precision treatment. See what this changes for mCRPC strategy.
What the TRACERx study reveals about Personalis’ MRD technology in NSCLC
Personalis, Inc. has reported pivotal findings from its NeXT Personal assay in a new Cell publication, highlighting the test’s ability to detect molecular residual disease in stage I to III non-small cell lung cancer. The study, part of the TRACERx initiative and led by Professor Charles Swanton of the Francis Crick Institute and University College […]
How Indivumed’s biospecimen strategy is powering functional tumor model development
Indivumed GmbH and the Wilmot Cancer Institute at the University of Rochester Medical Center have expanded their collaboration to accelerate the development of patient-derived tumor models and AI-informed therapeutic discovery for solid tumors with high unmet clinical need. What this collaboration changes for the cancer model ecosystem The expansion of the Indivumed and University of […]